Tag: WSC 2023
Tenecteplase deemed non-inferior to alteplase in suitable ischaemic stroke patients
The ATTEST-2 trial has found that tenecteplase was non-inferior to alteplase, the more established of the two thrombolytic agents, in suitable acute ischaemic stroke...
TENSION results show improved functional outcomes and reduced mortality with stroke...
New results from the TENSION study—presented recently at the 15th World Stroke Congress (WSC; 10–12 October, Toronto, Canada) by Götz Thomalla (University Medical Center...
